Sign in
Taking people in United StatesNo phase

Virtual reality added to linaclotide for irritable bowel syndrome with constipation

Tests virtual reality plus linaclotide in adults with constipation-type irritable bowel syndrome.

Key facts

Who runs it
Mayo Clinic
Where
Jacksonville, United StatesSee the site
Trial code
Registry title
A Study of Virtual Reality and Linaclotide for IBS-C
Status
Recruiting
People taking part
65 people, planned
Started
31 May 2024
Planned end
Oct 2026
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Virtual Reality
Record updated
29 July 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with irritable bowel syndrome with constipation (IBS-C) whose quality of life is affected. Everyone gets linaclotide plus either real or sham virtual reality therapy.

Age
18 to 70 years
Sex
Men and women
Disease stage
IBS-C by the Rome IV criteria, with a score below 65 points on the IBS-QOL quality of life questionnaire (at least moderate impairment).
Earlier treatment
People currently taking linaclotide (any dose) cannot join. People who had side effects from linaclotide before, or whose symptoms did not improve on it, cannot join.

Main reasons for not taking part

  • Other bowel or body conditions that can look like IBS, such as celiac disease, inflammatory bowel disease, HIV/AIDS, or diabetes with HgA1c >7.0
  • Severe depression or suicidal thoughts
  • Regular use of opioid pain medicines
  • Known seizure disorder, prior colon or bowel surgery, or a known pelvic floor disorder
  • Alcohol abuse, or not able to understand English

The registry criteria, word for word

Show all 15 criteriaShow less

Who can take part

  • Adult men and women (18-70) who meet Rome IV criteria for IBS-C
  • Patients will be required to score below 65 points on the IBS Quality of Life (IBS-QOL) instrument, indicating a score consistent with at least moderate HRQOL (Health-related quality of life) impairment

Who cannot take part

  • Patients with severe depression, defined as a score equal to or greater than two standard deviations (SDs) on the NIH PROMIS depression scale, or those with suicidal ideations, will also be excluded and provided with standard resources to support their mental health and referred back to their primary care provider, a member of the study team will follow up with the PCP to ensure the communication was received
  • Patients using regular doses of opioid medications will also be excluded given the often-severe impact of opioids on GI motility and potential for pharmacological visceral hyperalgesia
  • if they have had prior surgery to the colon,
  • Patients previously treated with linaclotide who reported side effects,
  • those currently on linaclotide (any dose),
  • Patients will be excluded from the study if they have a comorbid disorder that may confound the diagnosis of IBS, including celiac disease, inflammatory bowel disease, autoimmune disorders that affect the GI system, history of bowel resection, HIV/AIDS, diabetes with HgA1c >7.0, neuroendocrine tumors, microscopic colitis, lactase deficiency, eosinophilic bowel disease, acute intermittent porphyria, or any other condition that a licensed physician believes can mimic IBS symptoms and undermine diagnostic certitude
  • have a known seizure disorder,
  • if symptoms are thought to represent an organic disorder,
  • if symptoms represent a known pelvic floor disorder,
  • Patients will also be excluded from the study if they do not meet Rome IV criteria for IBS-C,
  • if the patient is abusing alcohol,
  • or if the patient cannot actively participate in the study for any other reason (e.g., inability to understand English as the VR program is in English only)
  • and those who did not note an improvement in IBS-C symptoms in the past while on linaclotide will also be excluded

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 70 years old?

Where in United States

  • Mayo Clinic FloridaJacksonville, United StatesContact: Brian Lacy, MD, PhDTaking people

About the trial

What the trial wants to find out

The purpose of this study is to determine if adult patients with IBS-C will report an overall greater improvement in IBS symptoms and quality of life when treated with a combination of linaclotide (standard of care medication) and immersive virtual reality (VR) therapy compared to those treated with linaclotide and sham (placebo) VR therapy.

The 2 groups in the trial

  • Sham VRSham treatment, for comparison

    Patients in the sham Virtual Reality group will receive the same brand of head mounted device (Oculus Quest 2), but will only have access to sham content. Both groups will receive standard of care linaclotide treatment 290 mcg.

    Treatment: Virtual Reality

  • Immersive VRExisting treatment, for comparison

    Patients in the immersive Virtual Reality group will receive a head mounted VR device Oculus Quest 2, and will receive active immersive content. Both groups will receive standard of care linaclotide treatment 290 mcg.

    Treatment: Virtual Reality

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Pilot Study to Evaluate the Efficacy and Safety of Virtual Reality in Combination With Linaclotide for the Treatment of Adults With IBS and Constipation Predominance
Plain-language title
Virtual reality added to linaclotide for irritable bowel syndrome with constipationGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Fit questions
Built from NCT05796388, who can take part
Record updated
29 July 2026